LXEO Stock Forecast: Lexeo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.96
+0.34% on the day

The median 12-month analyst price target for Lexeo Therapeutics, Inc. is $23. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$245.1M
Ticker Nerd rank
30/ 100
Median analyst target
$23
Analysts covering
9
Revenue$0.0
Operating income−$28.0M
Net income−$25.9M
Free cash flow−$17.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.1%
1M
−2.0%
YTD
−70.2%
1Y
−66.8%
From 52W high
−72.2%
From 52W low
+12.5%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Lexeo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
30/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
73
Quality
50
Volatility
46
Issuance
38
Accruals
37
Value
33
Momentum
31
Revisions
26

Growth (73): Sales and profits are climbing, and climbing faster than before.

Revisions (26): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LXEO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LXEO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26LXEOHigh $42Median $23Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$9
Low
$23
Median
$42
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Nov 2026Cantor FitzgeraldMaintainsOverweight$23 → $37
12 Nov 2026Cantor FitzgeraldReiteratesOverweight$23
23 Sept 2026Leerink PartnersMaintainsOutperform$15
25 June 2026JP MorganMaintainsOverweight$12 → $9.00
11 May 2026Chardan CapitalMaintainsBuy—
13 Jan 2026Chardan CapitalMaintainsBuy—
13 Jan 2026HC Wainwright & Co.MaintainsBuy—
18 Dec 2025Raymond JamesInitiatesStrong Buy—
11 Dec 2025Chardan CapitalMaintainsBuy—
1 Dec 2025Cantor FitzgeraldInitiatesOverweight—
20 Nov 2025Cantor FitzgeraldInitiatesOverweight—
6 Nov 2025Chardan CapitalMaintainsBuy—
5 Nov 2025Chardan CapitalMaintainsBuy$17
21 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Oct 2025GuggenheimInitiatesBuy—
7 Oct 2025Chardan CapitalMaintainsBuy—
7 Oct 2025HC Wainwright & Co.MaintainsBuy—
7 Oct 2025Leerink PartnersMaintainsOutperform—
15 Aug 2025Chardan CapitalMaintainsBuy—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LXEO.

Market Radar

This page is one stock. Monday covers all of them.

LXEO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LXEO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Lexeo Therapeutics, Inc. returned −66.8% against +6.9% for the S&P 500, dividends included.

LXEO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26LXEOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LXEO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.1×

Cheaper than 66% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−62.4%

Higher than 19% of US stocks

Return on assets
−36.7%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lexeo Therapeutics, Inc. has a market value of $245.1M and an enterprise value of $56.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$87.3M.

  • Diluted earnings per share, trailing twelve months: −$1.15.

  • Free cash flow in the twelve months to 30 June 2026: −$88.7M.

  • Shares outstanding: 78.6M.

  • Lexeo Therapeutics, Inc. employs 68 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

LXEO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LXEOLexeo Therapeutics, Inc.$245.1M30
TTRXTurn Therapeutics, Inc.$247.5M24
QTTBQ32 Bio, Inc.$248.2M61
EDITEditas Medicine, Inc.$251.7M67
CAMPCAMP4 Therapeutics Corp.$237.8M49
SABSSAB Biotherapeutics, Inc.$255.7M47
EIKNEikon Therapeutics, Inc.$256.4M5

Take a look at LXEO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Lexeo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LXEO

What is the LXEO stock price forecast for 2026-2027?

The median 12-month analyst price target for Lexeo Therapeutics, Inc. is $23, with estimates ranging from $9 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LXEO stock a buy right now?

Of the 9 analysts covering Lexeo Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexeo Therapeutics, Inc. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LXEO?

As at 21 Nov 2026, Lexeo Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (73 of 100).

Will LXEO stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts is $23, and Ticker Nerd's factor model ranks Lexeo Therapeutics, Inc. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LXEO stock forecast for 2030?

No analyst covering Lexeo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $42 over the next 12 months.

How has LXEO stock performed over the past year?

Lexeo Therapeutics, Inc. returned -66.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lexeo Therapeutics, Inc. do?

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need. Lexeo Therapeutics concentrates on genetically defined cardiovascular conditions and APOE4-associated Alzheimer’s disease, using AAV-based programs designed to address the underlying causes of disease.

Company

About Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need. Lexeo Therapeutics concentrates on genetically defined cardiovascular conditions and APOE4-associated Alzheimer’s disease, using AAV-based programs designed to address the underlying causes of disease. Its current pipeline includes therapies such as LX2006 for Friedreich’s ataxia cardiomyopathy, LX2020 for PKP2-related arrhythmogenic cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer’s disease. The company operates as a biotechnology developer rather than a commercial drug maker, with its work centered on research, clinical development, and advancing precision medicines through early- and mid-stage testing. Based in New York City, Lexeo Therapeutics plays a specialized role in the genetic medicine market by targeting serious conditions where conventional treatments remain limited.

CEO Mr. R. Nolan Townsend M.B.A. · 68 employees · United States · https://www.lexeotx.com